LBA27 Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC.

MLA

Strickler, J. H., et al. “LBA27 Additional Analyses of MOUNTAINEER: A Phase II Study of Tucatinib and Trastuzumab for HER2-Positive MCRC.” Annals of Oncology, vol. 33, Sept. 2022, p. S1394. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.08.023.

APA

Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J., Coveler, A., Fountzilas, C., Kardosh, A., Kasi, P. M., Lenz, H. J., Ciombor, K. K., Fernandez, M. E. E., Bajor, D. L., Stecher, M., Feng, W., & Bekaii-Saab, T. (2022). LBA27 Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC. Annals of Oncology, 33, S1394. https://doi.org/10.1016/j.annonc.2022.08.023

Chicago

Strickler, J.H., A. Cercek, S. Siena, T. André, K. Ng, E. Van Cutsem, C. Wu, et al. 2022. “LBA27 Additional Analyses of MOUNTAINEER: A Phase II Study of Tucatinib and Trastuzumab for HER2-Positive MCRC.” Annals of Oncology 33 (September): S1394. doi:10.1016/j.annonc.2022.08.023.